Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | TEK | Q02763 | 2/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16295085 | 0.89 | SLC2A1 (0.47) | PARP1ALDH1A1SLC2A1CHEK1PIM1 | |
| SCHEMBL16294645 | 0.88 | ENPP1 (0.50) | ENPP1ALDH1A1KDR | |
| SCHEMBL17967511 | 0.84 | SRC (0.49) | PARP1ALDH1A1SLC2A1CHEK1PIM1 | |
| SCHEMBL17967514 | 0.83 | ENPP1 (0.59) | ENPP1SRCKDR | |
| SCHEMBL16295087 | 0.79 | ENPP1 (0.44) | ENPP1ALDH1A1KDR | |
| SCHEMBL16294230 | 0.78 | ENPP1 (0.54) | ENPP1KDR | |
| SCHEMBL1998529 | 0.75 | SLC2A1 (0.54) | PARP1ALDH1A1SLC2A1CHEK1PIM1 | |
| SCHEMBL18013041 | 0.73 | PDE10A (0.38) | ALDH1A1FLT3MKNK1KDR | |
| SCHEMBL1999978 | 0.73 | ENPP1 (0.54) | ENPP1ALDH1A1MAPTKDR | |
| SCHEMBL17967513 | 0.73 | ENPP1 (0.41) | ENPP1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | EGFR, ERBB2, ERBB4 | ENPP1 1422/4885PARP1 1966/4885ALDH1A1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.